For a new formulation for amyloidosis

You are being invited to take part in a clinical study to evaluate an investigational medicinal product. An investigational medicinal product is a medicinal product that is still being studied to evaluate its efficacy, safety or mode of action.

Who may participate

This study is seeking healthy male and female participants. Participants must be healthy, meaning they will not have the condition for which this treatment is being developed and are in overall good health. In addition to the criteria listed, participants must meet the following requirements:

  • Willing and able to travel to our study facility in Brussels, Belgium
  • Able to comply with study appointments and procedures.
  • Body mass index (BMI) of 16 to 32 kg/m2; and a total body weight >45 kg.

  • Contraception:

    For men:
    No contraception methods are required for male participants in this study, given that research has shown that the study drug does not transfer through semen.

    For women:
    Women of non-childbearing potential: You may participate in this study, provided that:

    You are post-menopausal (meaning that your last period was at least one year ago, or

     you have been surgically sterilized (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy)

If you do not fall into one of the abovementioned categories, you will be considered as capable of having children. In this case, you will not be allowed to participate in this study.

There are other requirements for participation in this study. Please read attentively the Informed Consent Document (ICD), more explanation will be provided by the study staff during the screening process.

Condition

Healthy

Age

18+

Sex

Male/female without childbearing potential

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

What to expect

If this study may be a fit for you, you’ll be invited to a screening visit at our facility in Brussels, Belgium.

If you choose to participate, you will be in the study for up to 11 weeks, including the screening and follow-up period. You will be screened within 28 days prior to the first dose of study intervention.
Throughout the study, staff will closely monitor your health status and collect data.
You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.

View the calendar

How long is the study?

Approximately 11 weeks

Compensation

Up to € 3.456, plus travel fees